UnknownPhase EARLY_1

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Lead sponsor

Seoul National University Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Hypothalamic / syndromic obesity, Obesity / overweight

Eligibility highlights

•BMI ≤30

Primary endpoint

•Body weight, absolute change (kg)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06217848

Org study ID2208-031-1348

Timeline

Milestones

Study start2022-11-28actual

Study first posted2024-01-23actual

Last update posted2024-01-23actual

Primary completion2024-02-08estimated

Study completion2024-03-08estimated

Assets

Investigational agents

Liraglutide

Who this study enrolls

Hypothalamic / syndromic obesityObesity / overweight

Who can enroll

Minimum age19 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients diagnosed with a hypothalamic tumor and treated surgically with confirmed hypothalamic damage

•19 years of age or older

•Have a body mass index of at least 27 and less than 30 (27≤BMI<30) and one or more confirmed weight-related medical conditions, or a body mass index of 30 or greater (BMI≥30).

•Voluntarily agreed to participate in the study after receiving a full explanation of the study.

Exclusion criteria

•Unable to fully understand the instructions for participation in the study or unable to give voluntary consent.

•Presence or history of a medical condition or disease that, in the opinion of the investigator, would make it difficult for the patient to participate fully for the duration of the study or to interpret the results of the study

•Taking medications that may affect weight, except for hormone replacement therapy, in the last 6 months

•non-primary tumor patient

•Diagnosis of severe renal dysfunction, liver dysfunction, or thyroid disease among other underlying conditions

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Change in weight

Time frame:3 month

Body weight, absolute change (kg)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.